



KILPEST INDIA LIMITED

REGD. OFFICE & FACTORY :

7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 INDIA

Tel : 91-755 2586536, 2586537

E-mail : kilpest@bsnl.in
info@kilpest.com

Visit us at : www.kilpest.com

CIN : L24211MP1972PLC001131

November 29, 2022

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, Mumbai – 400001

Dear Sir / Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (“LODR Requirements”)

This is to inform you that 3B BlackBio Biotech India Limited, a subsidiary of Kilpest India Limited (“Kilpest”) has today, announced the signing of a non-binding Letter of Intent (LOI) to acquire 100% shares of a European based company that specializes in the development and manufacture of innovative high-quality products for the life science and molecular diagnostic markets.

A business update on the aforesaid LOI is enclosed as Annexure I for your perusal and information.

Further, pursuant to Regulation 30 (8) of the SEBI LODR Regulations, the enclosed business update is also made available on the company’s website.

Kindly take the same on record.

Yours faithfully,
For Kilpest India Limited

Navneet Kaur



Navneet Kaur
Company Secretary



Annexure - I

**3B BlackBio Biotech India Limited, a subsidiary of Kilpest India Limited plans to acquire 100% stake in a European Based manufacturer of Life Science Products**

Bhopal – November 29, 2022 – 3B BlackBio Biotech India Limited (a subsidiary of Kilpest India Limited) today, announced the signing of a non-binding Letter of Intent (LOI) to acquire 100% shares of a European based company that specializes in the development and manufacture of innovative high-quality products for the life science and molecular diagnostic markets.

The deal is subject to customary financial, legal and business due diligence, as well as regulatory approvals. An exclusivity period of 60 days has been agreed upon between the parties to complete the due diligence.

The acquisition of this business would represent a strategic investment in the related field of life science research and molecular diagnostics.

The acquisition will be funded fully with internal accruals by M/s 3B Blackbio Biotech India Ltd and its subsidiary M/s TRUPCR Europe Limited.

As per the Non-Disclosure Agreement signed with the company till the final agreement is concluded post due diligence, the name and other details of this LOI are not being disclosed. As soon as the final binding agreement is executed, all the detailed information about the deal shall be disclosed immediately.

About 3B BlackBio Biotech India Limited

As a subsidiary of Kilpest India Limited, 3B BlackBio is an R&D driven company which develops, validates, and manufactures a range of qPCR (TRUPCR®) molecular diagnostic assays for the oncology and infectious disease markets. With over a decade of experience and more than 100 products developed and launched, the company ensures in delivering high quality patient care through our diagnostic solutions. As an ISO13485:2016 accredited company, the molecular diagnostic kits are developed and manufactured in line with the highest possible standards. 3B BlackBio's subsidiary, TRUPCR Europe, based in Manchester, UK, serving as its European HQ will also be soon certified ISO13485 and begin manufacturing MDx kits later in this financial year.

Naresh Kumar
KILPEST INDIA LIMITED
BHO PAL